Cluster C: 9 Molecular Epidemiology Resource

分子流行病学资源(MER)是一种新的共享研究资源提供 HCCC调查人员支持高质量的特定疾病结果研究。美人鱼 提供详细的纵向临床数据和生物样本的收集，包括血清， 血浆和生殖系DNA，都可与肿瘤样本相关联，与 组织采购核心。 HCCC的战略规划工作确定了强大的基础设施的重要性， 便于将分子和临床结果数据联系起来。合并是这一过程中的关键组成部分 新的基础设施。由于这样的努力代价巨大，MER将其重点放在了 针对具有必要临床和研究实力的疾病特定群体所做的努力 利用生成的数据。目前MER支持的特定疾病小组包括 淋巴瘤、黑色素瘤和肉瘤、骨髓瘤以及乳腺癌、胰腺癌和胃腺癌。 MER是一个严格的、前瞻性的观测数据库，链接到一个生物储存库。都是新的 由调查人员选择具有适当组织学特征的确诊患者 关于知情同意。注册后，MER人员提取临床信息 包括肿瘤分期、组织学、实验室和影像资料、治疗方式、治疗反应、 事件(进展、死亡)和共病。一般来说，每个受试者的临床信息是 每年更新2次，为期3年，然后每年更新一次。心理社会数据，包括生活质量分析 是纵向收集的。血清、血浆、棕黄色涂层和外周血DNA(诊断时 和选定的纵向时间点)，以及多余的手术组织(肿瘤和 正常)与组织采购中心合作进行切除和活组织检查。这个 定期验证临床数据，使其在没有调查人员的情况下即可进行分析 需要返回到医疗记录。 到目前为止，已有5,000多名受试者参加了MER。2014年，35名调查人员，其中 26人是HCCC成员与HCCC成员合作询问癌症问题， 利用聚合体材料。用户来自HCCC的四个科学项目中的每一个。数据， 过去曾与NCI指定的其他5个癌症中心共享生物素或两者兼而有之 年。

The Molecular Epidemiology Resource (MER) is a new shared research resource offering HCCC investigators support for high quality disease-specific outcomes research. The MER offers meticulous collection of longitudinal clinical data and biologic specimens including serum, plasma and germline DNA, all linkable to tumor samples catalogued in coordination with the Tissue Procurement Core. The HCCC strategic planning effort identified the importance of a robust infrastructure that facilitates linking molecular and clinical outcomes data. The MER is a critical component of this new infrastructure. Because the cost of such an effort is significant, the MER has focused its efforts on disease-specific groups that have the necessary clinical and research strength to utilize the resulting data. Current disease-specific groups supported by the MER include lymphoma, melanoma and sarcoma, myeloma, and cancers of the breast, pancreas, and GU. The MER is a rigorous, prospective observational database linked to a biorepository. All newly diagnosed patients with appropriate histologies as selected by the investigators are approached about informed consent. Following enrollment, MER personnel abstract clinical information including tumor stage, histology, lab and imaging data, treatment modality, treatment response, events (progression, death) and comorbidities. In general, clinical information on each subject is updated 2x/year for 3 years, then annually. Psychosocial data including quality-of-life analyses are collected longitudinally. Serum, plasma, buffy coat and peripheral blood DNA (at diagnosis and selected longitudinal time points) are collected, as is excess surgical tissue (tumor and normal) from resections and biopsies in collaboration with the Tissue Procurement Core. The clinical data are periodically validated to enable their readiness for analysis without investigators needing to return to the medical record. Over 5,000 subjects have been enrolled in the MER to date. In 2014, 35 investigators, of whom 26 were HCCC members were asking cancer questions in collaboration with HCCC members, utilized MER materials. Users came from each of the HCCC's four scientific programs. Data, biospecimens or both have been shared with 5 other NCI-designated cancer centers in the past year.